Primary respiratory tuberculosis
Chapter 1:Certain infectious and parasitic diseases
ICD-10 A15.7 is a billable code used to indicate a diagnosis of primary respiratory tuberculosis.
Primary respiratory tuberculosis is an infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs. It is characterized by the initial infection that occurs when the bacteria are inhaled, leading to a localized inflammatory response in the lung tissue. Patients may present with symptoms such as persistent cough, chest pain, hemoptysis, fever, night sweats, and weight loss. Diagnosis typically involves a combination of clinical evaluation, chest X-rays, and microbiological tests, including sputum smear microscopy and culture for Mycobacterium tuberculosis. The disease can be asymptomatic in its early stages, making screening and early detection crucial, especially in high-risk populations. Treatment usually involves a multi-drug regimen over a period of at least six months, with close monitoring for adherence and potential drug resistance. Public health measures, including contact tracing and isolation of infectious cases, are essential to control the spread of tuberculosis. Drug resistance, particularly multidrug-resistant tuberculosis (MDR-TB), poses significant challenges in treatment and requires specialized management strategies.
Detailed clinical notes on symptoms, diagnostic tests, treatment plans, and follow-up care.
Diagnosis and management of active tuberculosis, monitoring for drug resistance, and public health reporting.
Consideration of co-morbid conditions and potential drug interactions.
Comprehensive pulmonary function tests, imaging studies, and treatment response evaluations.
Management of respiratory symptoms in patients with tuberculosis and assessment of lung function.
Need for coordination with infectious disease specialists for comprehensive care.
Used for screening high-risk populations for tuberculosis exposure.
Document the reason for testing and results.
Infectious disease specialists may require additional follow-up testing.
Common symptoms include a persistent cough, chest pain, hemoptysis, fever, night sweats, and weight loss. Some patients may be asymptomatic in the early stages.
Diagnosis typically involves a combination of clinical evaluation, chest X-rays, and microbiological tests such as sputum smear microscopy and culture.
Treatment usually involves a multi-drug regimen, including isoniazid, rifampin, ethambutol, and pyrazinamide, administered over a minimum of six months.
Public health measures include contact tracing, isolation of infectious cases, and monitoring for drug resistance.
